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The editorial by Moghbel and colleagues published in this
issue of the European Journal of Nuclear Medicine and
Molecular Imaging raises a number of concerns with regard
to amyloid-beta (Aβ)i m a g i n g[ 1]. We appreciate the
opportunity to address and clarify these concerns by referring
to the scientific literature. There are several issues raised by
Moghbel and colleagues which we acknowledge require care-
ful consideration, further discussion, and research, including
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imaging, and the role of Aβ pathology in disease generation.
However, the editorial by Moghbel and colleagues brings into
question the very feasibility of imaging Aβ in the brains of
living humans [1]. Many of the issues raised in the editorial
have been extensively researched and discussed in various
scientific venues and publications over the past decade. How-
ever, itmay be worthwhile tocommunicatethese findingstoa
larger community, including scientists not active in this par-
ticular field ofresearch. Thus, to avoid further misunderstand-
ings and foster discussion based upon common grounds of
knowledge in the future, we will try to address the issues
raised by Moghbel and colleagues point by point and summa-
rize the corresponding evidence in the following order: (1)
alleged anomalies in the distribution of Aβ radiotracers, (2)
perceived difficulties in visualizing Aβ plaques, (3) concerns
about the binding properties of Aβ radiotracers to plaques,
and (4) questions regarding the theoretical basis of Aβ
imaging.
Alleged anomalies in the distribution of Aβ radiotracers
Moghbel and colleagues point out two issues regarding the
regional distribution of Aβ radiotracers. One is a limitation
of all existing Aβ radiotracers: nonspecific white matter
retention. This phenomenon is well known, having previ-
ously been demonstrated in in vitro studies with human
brain (see Fig. 4 of [2], Figs. 1C&D of [3], and Fig. 2 of
[4]), in animal studies, (see Fig. 3 of [5]), and from the very
beginning of in vivo human studies (see Fig. 3B of [4]). In
hundreds of subjects, it has been shown that the level of this
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210 Eur J Nucl Med Mol Imaging (2012) 39:209–219nonspecific white matter retention does not differ between
Alzheimer’s disease (AD) patients and normal controls
[6–9]. Given that regional cerebral blood flow in white
matter is approximately 40–50% of that in neocortex [10,
11], slower clearance of tracers [12] likely contributes to Aβ
radiotracer retention in white matter [4, 13]. This nonspe-
cific retention continues to represent a challenge to optimiz-
ing the analysis of Aβ imaging positron emission
tomography (PET) data. It is true that spillover can occur
from this nonspecific retention into neighboring gray matter
(and vice versa when gray matter contains high amounts of
fibrillar Aβ). However, it should be mentioned that due to
the relatively small width of the cortical gray matter, which
can be below the resolution of a PET scanner, the partial
volume effect is not a problem unique to Aβ imaging but
affects PET imaging procedures of the brain in general.
Furthermore, in Fig. 2 of Moghbel et al., a representation
of the partial volume effect is given that is not appropriate
for Aβ imaging. Moghbel et al. refer to work in malignant
lung lesions where the intensity differences are indeed huge
and “overwhelming” [14]. In contrast, the typical retention
of Aβ radiotracers in gray matter is not a small fraction of an
overwhelming level of white matter retention as depicted,
but at least comparable to threefold higher in typical Aβ-
positive scans. Nevertheless, it is clear that the white matter
uptake and the corresponding partial volume effects may lead
to inaccuracies in the precise quantification of cortical tracer
retention and thus assessment of cortical Aβ. While common
to all Aβ radiotracers, this is more noticeable in currently
published studies using
18F-labeled Aβ radiotracers, which
appear to generally show somewhat higher white matter re-
tention as compared to
11C-labeled Pittsburgh Compound-B
(PiB) [4, 7, 9,15–17].However, this limitationhas not proven
to be a major hurdle to the quantitation of Aβ deposits in
cortical gray matter, neither in the in vivo/postmortem cross-
validation studies, nor in studies on the predictive value of the
Aβ imaging findings, with regard to future cognitive decline.
Nevertheless, there is room for further improvement in this
context with regard to the development of tracers with less
white matter retention and of image evaluation techniques
(such as partial volume correction algorithms/volume of
interest-based techniques for selective identification of gray
matteruptake)[18–20].Finally,itneedstobeemphasizedthat
for many clinical purposes, answering the question of the
general presence of Aβ pathology in the brain with YES or
NO by visual assessment will be of higher priority than
absolute quantification and localization of these abnormali-
ties. For example, in routine clinical practice, fluorodeoxyglu-
cose (FDG) PET data of the brain are read without partial
volume correction and the interpretation is usually established
without absolute quantification of the findings.
A second alleged discrepancy between Aβ tracer reten-
tion and Aβ pathology—the claim that the frontal lobes do
not harbor very high Aβ deposition in AD—is contradicted
by a wealth of existing data. Thal et al. have clearly dem-
onstrated heavy and early frontal Aβ deposition [21]. In
their classic 2002 paper, this group (led by Heiko Braak)
stated that in the earliest phase of Aβ deposition (phase 1)
“there are Aβ deposits in the frontal, parietal, temporal, or
occipital neocortex” [21] and Fig. 2 of this group’s 1997
paper based on the examination of 2,661 brains clearly
shows early and predominant basal frontal and anterior
temporal Aβ deposition [22] (Fig. 1).
Numerous other neuropathological studies recapitulate
these findings. In fact, the lead author of the paper that
Moghbel et al. lean upon most heavily [23] later published
a report showing that very high plaque density is found in
the frontal cortex in AD [24]. An even more recently pub-
lished work by this group demonstrated good correlation of
an
18FA β tracer to pathologically determined Aβ load in
biopsies of the frontal cortex [25]. Despite the fact that
neuropathological studies consistently detect a high Aβ
plaque load in frontal cortex, neuropathological measures
of percent plaque area are only semiquantitative and are
complicated by variations caused by the fluorescence prop-
erties of the dyes used or secondary reactions used to am-
plify Aβ-antibody binding. Therefore, this may not be the
most appropriate comparison to Aβ imaging. A more ap-
propriate postmortem analysis would be truly quantitative
assessments such as enzyme-linked immunosorbent assay
(ELISA) analysis of Aβ load [26, 27]. In their benchmark
study of 79 postmortem brains, Näslund et al. clearly show
that frontal cortex typically contains two- to fourfold higher
levels of total Aβ than temporal, entorhinal, parietal, or
visual cortices [26]. In summary, the contention by Moghbel
and colleagues that the frontal lobe is not a prominent site of
Aβ deposition is inconsistent with the current state of
knowledge regarding the neuropathology of AD.
The suggestion by Moghbel and colleagues that congo-
philic angiopathy (CAA) could be responsible for Aβ tracer
retention in the frontal cortex also does not follow from the
neuropathology literature. Several studies (including a re-
cent one they cite [28]) clearly identify the occipital lobe as
the site of highest Aβ deposition in CAA, but the occipital
lobe is one of the lowest neocortical sites of Aβ radiotracer
retention in AD [6, 29].
Moghbel et al. also claim that structural and functional
changes such as regional atrophy, hypoperfusion, or hypo-
metabolism should serve as a predictor of regional Aβ
pathology. However, evidence that these processes are as-
sociated with regional postmortem Aβ pathology is sparse.
For example, while brain atrophy may indeed occur in some
areas of the brain affected by Aβ pathology, the data suggest
that these abnormalities are sequential, and that Aβ
deposition precedes synaptic dysfunction and neuronal
loss [30–32], which are then evidenced as structural
Eur J Nucl Med Mol Imaging (2012) 39:209–219 211changes [33]. This may very well explain the regional
discrepancies between patterns of atrophy and Aβ de-
position detected by in vivo imaging studies [34]. At
any rate, these considerations revolve around the inter-
action of different neurodegenerative pathologies and do
not relate to the value of Aβ imaging to accurately
measure the presence of Aβ in the brain.
The strongest proof of the feasibility of Aβ imaging to
accurately measure Aβ deposition in vivo is founded on a
wealthofdetailedAβPET-neuropathologycorrelativestudies
that demonstrate the close match between in vivo Aβ radio-
tracer retention and postmortem Aβ pathology as assessed by
ELISA,immunohistochemistry,Bielschowskysilverstaining,
orquantitativeinvitroassessmentoftritiatedPiBbinding[25,
35–43]( F i g .2). Further support is added by the fact that high
retention ofAβ radiotracers closely corresponds with: (1) low
CSFAβ levels, (2) presence of the apolipoprotein E ε4 allele,
and (3) increasing age [44–47].
To make this argument even stronger, those subjects with
a different regional distribution of Αβ in the brain such as
those carrying one of the mutations associated with autoso-
m a ld o m i n a n tA D[ 48–50], or familial British dementia
[51], or subjects with posterior cortical atrophy [52–55]o r
CAA [56, 57] show a different regional distribution of PiB
retention. If the retention of Aβ radiotracers was determined
by nonspecific factors as much as Moghbel and colleagues
suggest, then all scans would look relatively similar. The
sharp distinction between the regional pattern of PiB
Fig. 1 “Development of
amyloid deposits in 2,661
nonselected autopsy cases. The
first line displays the frequency
of cases devoid of changes in
relation to the total number of
cases in the various age
categories. The second, third,
and fourth lines are similarly
designed, and show the
evolution of the AD-related
changes. The dark areas of the
columns refer to subgroups
showing the presence of neuro-
fibrillary changes.” (reproduced
with permission from Neurobiol
Aging,[ 22])
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sporadic AD (Fig. 3)—corresponding to the known patterns
of Αβ aggregation in their brains—makes a convincing argu-
ment for specific Aβ-driven retention of Aβ PET tracers.
Perceived difficulties in visualizing Aβ plaques
Moghbel and colleagues raise the concern that Αβ plaques
in the brain are too small to allow in vivo imaging by means
of PET. This argument would not only render Aβ imaging
as impractical, but it would argue against the possibility of
imaging structures/processes of even smaller size (i.e., mo-
lecular imaging in general), such as neuronal glucose me-
tabolism (regularly imaged with FDG) or the receptor
density on cell membranes. Aβ imaging does not attempt
to resolve an individual 50–100 μmA β plaque. That futile
effort would indeed be thwarted by the limited resolution of
PET and the partial volume effects described. However,
partial volume effects not only decrease the signal within a
small structure such as a plaque due to low-signal bleed-in,
butpartialvolumeeffectsalsoincreasethesignalintheplaque
penumbrabyhigh-signalbleed-out.Theneteffectisablurring
of the signal on a submillimeter scale, but without significant
loss of total signal on a larger scale. Like any other PET
technique, Aβ imaging assesses the average concentration
ofAβ radiotracer binding sites withina regionofinterest. Just
as one dopamine receptor would be swamped by neighboring
receptor-free tissue but millions of dopamine receptors pro-
duce a strong
11C-raclopride signal in the striatum, also
millions offibrillar Aβ deposits produce a signal that is easily
detectable in Aβ-laden parts of gray matter.
Another concern brought up by Moghbel and colleagues
is based on the surprising and unsupported assumption that
the mass of Aβ in mild cognitive impairment (MCI) would
be 60-fold less than (i.e., 1–2% of) that in AD, thus not
possibly providing enough target structures for successful
imaging. This assumption is not supported by data of neuro-
pathological studies. In contrast, the quantitative postmortem
data of Näslund et al. showed that subjects who die at the
Clinical Dementia Rating (CDR) 0.5 stage (typically consid-
ered MCI) had an Aβ load 25–76% of that seen in patients
with established dementia (CDR of 1.0 or greater) [26].
Even in groups of autopsy cases consisting of early or
mild-moderate AD, neocortical amyloid markers are not
significantly different when compared to those in MCI cases
[58]. A recent review summarized the extent of amyloid
pathology in MCI relative to cognitively normal people
and early AD [59].
There is ample Aβ in the neocortex of AD and MCI
patients and many normal controls to be detected with Aβ
Fig. 3 Comparison of the regional distribution of PiB retention in a
presenilin-1 mutation carrier (left) and a sporadic case of AD (right).
The MRI is shown in gray and PiB retention is overlaid in a hot metal
scale on transaxial (top), sagittal (middle), and coronal images (bottom)
Fig. 2 Correlations of the in
vivo PiB distribution volume
ratio (DVR) values with
postmortem quantifications of
[
3H]PiB binding (E) and total
insoluble Aβ (Aβ1-40+Aβ1-42)
peptide levels (F) in 19 brain
regions from fresh-frozen tissue
from the right hemisphere of the
same Alzheimer’s disease sub-
ject. (reproduced with permis-
sion from Brain,[ 36])
Eur J Nucl Med Mol Imaging (2012) 39:209–219 213radiotracers. The nominal concentration of Αβ in AD front-
al cortex is ∼3 μM[ 26, 27, 60], which is about twofold the
number of PiB binding sites measured in vitro under satu-
rating conditions [60] (and in the mid-nanomolar range
under non-saturating conditions [61]). This is several orders
of magnitude higher than the concentration of many recep-
tors successfully assessed by PET. A recent paper demon-
strated that, even under non-saturating conditions, there are
about the same number of binding sites available in frontal
and temporal cortex in postmortem human AD tissue [∼60
fmol/mg tissue (∼60 nM)]. The authors concluded that “the
observed binding of [
11C]PIB to amyloid plaques in vitro in
human AD tissue, but not in healthy controls, is in corre-
spondence with in vivo studies of patients with AD. This
radiotracer is therefore very suitable in the early diagnosis
of AD and can be used for the detection of pathological
changes before there is a significant loss in cognitive func-
tion.” [61]. This, along with the high affinity of the PET
radiotracers for Aβ, renders the concerns about visualizing
Aβ plaques inconsistent with a wealth of existing data.
Concerns about the binding properties of Aβ plaques
Moghbel and colleagues also propose that there may be
“inherent difficulties of targeting fibrillar amyloid plaques,
which are not as well-defined as the soluble forms of the
protein.” Since the soluble (including oligomeric) forms of
Aβ are not well defined at all, it is difficult to interpret this
concern. In principle, conversion of a number of available
binding sites from a soluble to a more solid or immobile
status would be expected to increase the binding of a suit-
able ligand. For example, decreasing the mobility of recep-
tors by fixation to a solid support can increase the binding of
ligands [62, 63] because of decreased entropy and increased
rebinding of small molecule ligands [64]. Currently, there
are no data to support the idea that Aβ radiotracer binding to
insoluble Aβ fibrils is fundamentally different than any
other binding interaction of a radioligand with specific
binding sites on other proteins (many of which are relatively
immobile because they are embedded in membranes). In
fact, the binding of Aβ radiotracers to Aβ fibrils shows
typical, reversible binding properties in in vitro kinetic
binding analyses [18].
The authors point out that no in vivo studies using high
doses of unlabeled Aβ PET ligand to compete off the
specifically bound Aβ radiotracer have been performed to
validate the specific and reversible nature of binding in
humans. This is true and will likely remain true for two
reasons: (1) the nominal concentration of Aβ radiotracer
binding sites is on the order of 1 μM in AD cortex [26,
27, 60], requiring micromolar levels of unlabeled ligand to
effectively compete off the Aβ radiotracer; and (2) none of
the Aβ tracers have been approved for human use at the
doses required to achieve micromolar levels in brain. While
it might be possible to perform such studies in animals, there
are significant problems using Aβ radiotracers in transgenic
mouse models of AD [60, 65], although some of these
problems may be possible to overcome [66].
A more pertinent concern that Moghbel et al. correctly
point out is that there are different tertiary forms of Aβ
deposited in brain, such as the amorphous deposits in cere-
bellum which have very low affinity for all Aβ radiotracers.
This conformational variability also may come into play in
autosomal dominant forms of AD [48, 67]a n di ne a r l y
stages of Aβ deposition [37], but the significance of non-
fibrillar Aβ in typical, sporadic, late-onset AD is unknown.
Studies assessing the selectivity of PiB for other aggregated
misfolded proteins present in AD, such as tau/neurofibril-
lary tangles [36, 68] and α-synuclein/Lewy bodies [69, 70]
utilizing in vitro methods that are more pertinent to PiB
binding in vivo, have shown that in vivo cortical retention
of
11C-PiB primarily reflects fibrillar Αβ deposits. The
potentially differential affinity of the Aβ tracers to various
forms of Aβ deposits does not necessarily affect the clinical
utility of Aβ imaging. For example, the case mentioned by
Moghbel and colleagues [37] did not meet two commonly
used sets of neuropathological criteria for AD [71, 72],
because only sparse neuritic plaques and neurofibrillary
tangles were present, although the case did meet the older
Khachaturian criteria [73]. Nevertheless, it is important to
keep in mind that different conformations of Aβ deposits in
the brain [74] may affect the binding pattern of the tracers
and that Aβ imaging modalities may not recognize all types
of Aβ pathologies with equal sensitivity. This may be an
interesting area of future research, to further improve the
understanding of the quantitative information provided by in
vivo Aβ imaging methods. However, any additional
insights in this regard would rather lead to assigning a more
specific information to the Aβ imaging signal than putting
the general utility of this method into question.
Questions regarding the theoretical basis of Aβ imaging
Finally, Moghbel and colleagues broaden their concerns
well beyond issues related to PET imaging by questioning
the Aβ cascade hypothesis itself. This would imply that if
Aβ deposition is not causative of AD, it is not worth
measuring. In this context, it is important to draw a clear
distinction between the value of Aβ imaging and the merits
of the Aβ hypothesis—a hypothesis that remains supported
by the bulk of existing data [75]. The basic feasibility of
imaging AD pathology in vivo should not be confused with
a discussion of the causal relevance of Aβ in AD. In
isolation, Aβ imaging is not diagnostic, it is agnostic—that
214 Eur J Nucl Med Mol Imaging (2012) 39:209–219is, agnostic to the role of Aβ deposition in AD. Aβ imaging
was intended to assess the pathology of AD in vivo. This
tool may ultimately be used to help prove or disprove the
Aβ hypothesis of AD. The Aβ cascade hypothesis, though
important, is not highly relevant to the feasibility and valid-
ity of Aβ imaging since, by definition, Aβ deposition
remains a pathological hallmark of this disease.
Further, Moghbel et al. suggest that if Aβ deposition is
causative, then the levels of Aβ in brain should correlate
with cognition. Again, Aβ imaging is not a tool to assess
cognition. In contrast, it may represent a tool to detect Aβ
pathology independently and in particular before the onset
of clinically significant cognitive symptoms. For example, a
number of studies that have demonstrated the predictive
value of Aβ pathology in subjects with MCI with regard
to subsequent cognitive decline support this notion [76–79].
The long-recognized discrepancy between cognitive impair-
ment and Aβ plaque burden in the brain [80]m a yb e
explained by three factors: (1) a dissociation in timing be-
tween early disease events and subsequent events that are
more directly related to cognition [81]; (2) cognitive changes
may be more related to the long-term, cumulative effects of
soluble, oligomeric forms of Aβ (not apparent by routine
neuropathology or imaged by current PET tracers) [82, 83];
and (3) the importance of cognitive reserve in the modulation
of symptoms in the presence of brain pathology [84, 85].
Moghbel and colleagues further discuss the “noteworthy
rates of false-positive and false-negative PET scans using
amyloid tracers” [1]. This appears to reflect conceptual
misunderstanding and terminological imprecision. A person
with a positive Aβ PETscan who is negative for clinical AD
should not be regarded as a “false-positive” but rather cor-
rectly classified as an “Aβ-positive” non-demented subject.
This was clarified in the original report using PiB PET [4]a s
follows, “Therefore, at the outset, it may be best to not
equate amyloid deposition to clinical diagnosis. Rather than
as a method of diagnosis, it might be best to first think of
PiB retention more fundamentally as a method to detect and
quantify brain β-amyloidosis, a term first used in reference
to AD by Glenner [86].” Aβ imaging simply detects cerebral
β-amyloidosis. It does not provide a diagnosis by itself. It is
only one tool to be used along with clinical assessment and
other biomarker modalities to enhance our ability to provide
earlier and more accurate diagnoses. The “false-positives”
and “false-negatives” to which Moghbel et al. refer are
mismatches between the presence of cerebral β-
amyloidosis and symptoms of dementia. They are not
false-positives and false-negatives for the presence of Aβ.
The latter can only be determined by PET-neuropathology
correlations and to date, there have been essentially no
reported false-positives and only the rare false-negatives
that would be expected when comparing an in vivo tech-
nique with a highly sensitive tissue stain [41, 87].
Summary
We acknowledge that there are a number of caveats with
regard to the clinical value of Aβ imaging. This includes
disorders other than AD which may show Aβ deposition
(such as dementia with Lewy bodies), the unknown time to
conversion in healthy Aβ-positive persons or the relative
plateauing of the Aβ burden in later stages of disease [79,
87–90]. However, these caveats are not related to the proven
functionality of the tracers and should not hamper the appli-
cationandfurtherevaluationofinvivoAβimagingwithPET.
The fact that Aβ deposits can be detected by Aβ imaging
in vivo is, in our opinion, a fact substantiated by a wealth of
peer-reviewed data.
18F-Labeled Aβ imaging radiotracers
may be approved for clinical use in the near future. If so, this
will be the first PET radiopharmaceutical developed com-
mercially and the first PET tracer approved for clinical use
by the US Food and Drug Administration (FDA) since
FDG. As such, it represents a landmark moment in the field
of molecular imaging and should encourage further com-
mercial investment and development in the field. The func-
tionality, sensitivity, and specificity of Aβ plaque imaging
agents has by now been demonstrated in a level of detail and
reliability (including in vivo-to-postmortem autopsy corre-
lations) that has not been required or provided for most other
imaging tracers clinically used today. Many of the concerns
raised by Moghbel and colleagues in their current editorial
in the European Journal of Nuclear Medicine and Molecu-
lar Imaging have been resolved previously, and we attemp-
ted to summarize the available information on these issues,
to allow a future rational discussion on common grounds of
knowledge. As is the case for any clinical test, Aβ
imaging does not represent a perfect tool and some
justified concerns remain, such as the nonspecific white
matter retention or the effects of atrophy and partial
volume on quantification. However, none of these con-
cerns reasonably question the general feasibility of Aβ
imaging or have been demonstrated to hamper the value
of this procedure for detection of fibrillar Aβ pathology.
A discussion regarding clinical indications for Aβ im-
aging is as welcome and important as the debate about
the causal role of Aβ pathology in the genesis of AD.
However, both of these topics clearly need to be treated
independently from the feasibility of Aβ imaging itself.
Thus, we believe that the remaining issues do not justify a
call to slow the clinical development of these radiotracers
and to withhold the availability of this technology from
those it could potentially help. In contrast, we believe that
hindering the progress of this exciting new molecular
imaging approach could send an erroneous and discourag-
ing signal to groups interested in the development of other
new diagnostic agents. The inability to obtain the informa-
tion provided by Aβ imaging would most certainly slow
Eur J Nucl Med Mol Imaging (2012) 39:209–219 215down the urgently needed progress in understanding the
basics of neurodegeneration and in the development of new
approaches aiming to treat these devastating disorders. Aβ
imaging has been repeatedly held up as one of the major
successes of the past decade in the fight against AD. Thus,
rather than to unnecessarily question the general feasibility of
Aβ imaging, we believe we should vigorously foster the
applicationofthisuniquenewtooltoimproveourunderstand-
ing of AD pathophysiology, to aid clinical diagnosis, and to
advance the development of effective therapy.
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